Pasireotide - A somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease

IDrugs

Volumn 10, Issue 12, 2007, Pages 885-895

  Ben Shlomo, A ^a   Melmed, S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE RECEPTOR; ADRENERGIC RECEPTOR; ANGIOPEPTIN; BENZODIAZEPINE RECEPTOR; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DOPAMINE RECEPTOR; GHRELIN; GLUCAGON; GLUCOSE; GROWTH HORMONE; HISTAMINE RECEPTOR; INSULIN; MESSENGER RNA; OCTREOTIDE; PASIREOTIDE; PLACEBO; PROLACTIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNINDEXED DRUG; VATALANIB;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACROMEGALY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CORTICOTROPIN RELEASE; CUSHING DISEASE; DIARRHEA; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; ECG ABNORMALITY; FATIGUE; FECES COLOR; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HEADACHE; HUMAN; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY PAIN; LEG CRAMP; LOW DRUG DOSE; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ACROMEGALY; ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMAN GROWTH HORMONE; HUMANS; NEUROENDOCRINE TUMORS; OLIGOPEPTIDES; PITUITARY ACTH HYPERSECRETION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36549070665     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. 176834 Lanreotide launched in France. SCRIP 1995 2021 20
2. 454536 SOM230: A novel somatostatin peptidomimetic with broad somatotropin release-inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G EUR J ENDOCRINOL 2002 146 5 707-716
3. 458076 Treatment with the novel somatostatin analogue SOM230 reduced hyperglycemia and improved insulin sensitivity in diabetic and insulin-resistant monkeys. Gao J, Valentin M, Paladini S, Gutierrez C, Vogt G DIABETES 2002 51 Suppl 2 A250-A251
4. 460839 Octreotide. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ N ENGL J MED 1996 334 4 246-254
5. 460845 Somatostatin and its receptor family. Patel YC FRONT NEUROENDOCRINOL 1999 20 3 157-198
6. 471806 SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates and dogs. Weckbecker G, Briner U, Lewis I, Bruns C ENDOCRINOLOGY 2002 143 10 4123-4130 • The study demonstrated that pasireotide inhibited the GH/IGF-1 axis across species, and displayed a longer-lasting inhibitory effect than octreotide.
7. 477293 Annual report 2002: Novartis. Novartis AG ANNUAL REPORT 2003 January 23
8. 487493 Drug Datasheet: Sandostatin LAR Depot (octreotide acetate) for injectable suspension. DRUG DATASHEET WEBSITE 2002 September 01
9. 511390 A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns C J MED CHEM 2003 46 12 2334-2344 • The study describes in detail the drug design approach and analysis of the binding affinity of pasireotide for the somatostatin receptor subtypes.
10. 528248 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S J CLIN INVEST 1997 100 9 2386-2392
11. 670284 Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. Kvols L, Wiedenmann B, Oberg K, Glusman JE, O'Dorisio TM, De Herder W, Gao B, Arnold R, Anthony L PROC AM SOC CLIN ONCOL 2006 25 Abs 4082
12. 684184 The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, Melmed S J CLIN ENDOCRINOL METAB 2004 89 6 3027-3032
13. 684185 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A et al J CLIN ENDOCRINOL METAB 2004 89 4 1577-1585
14. 684186 A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T et al J CLIN ENDOCRINOL METAB 2004 89 2 638-645
15. 684190 SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: Mediated through somatostatin subtype receptor 3? Ruan W, Fahlbusch F, Clemmons DR, Monaco ME, Walden PD, Silva AP, Schmid HA, Kleinberg DL MOL ENDOCRINOL 2006 20 2 426-436
16. 684197 Unique structural elements profoundly influence the conformation of SOM230. Oberer L, Bovermann G, Ehrhardt C, Lewis I BIOPOLYMERS 2003 71 3 373
17. 684203 Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA EUR J ENDOCRINOL 2005 153 3 R7-R10
18. 684204 Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, Lamberts SW CLIN PHARMACOL THER 2005 78 1 69-80
19. 684205 Regulation of ghrelin secretion by somatostatin analogs in rats. Silva AP, Bethmann K, Raulf F, Schmid HA EUR J ENDOCRINOL 2005 152 6 887-894
20. 684206 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Schmid HA, Schoeffter P NEUROENDOCRINOLOGY 2004 80 Suppl 1 47-50
21. 684211 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A et al EUR J ENDOCRINOL 2005 152 4 645-654
22. 692590 Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terrenis MR, Khalaf S, Jordan S, Czirjak S et al EUROPEAN JOURNAL OF ENDOCRINOLOGY 2006 155 2 371-379
23. 745844 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A J CLIN ENDOCRINOL METAB 2006 91 11 4482-4488
24. 761556 Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues. Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET, Sandler S REGUL PEPT 2007 138 1 1-9
25. 761557 The pharmacokinetic-pharmacodynamic (PK-PD) relationship of pasireotide (SOM230), a novel somatostatin analogue, in patients with acromegaly. Lee L, Glusman J, Gao B, Buchelt A, Deckert F, Schran H J CLIN PHARMACOL 2006 46 9 1086 Abs 107
26. 783664 NCT00434148: Safety and efficacy of different dose levels of pasireotide in patients with de novo, persistent or recurrent Cushing's disease. Novartis AG CLINICALTRIALS.GOV 2007 July 03
27. 786167 The clinical role of somatostatin analogues as antineoplastic agents: Much ado about nothing? Hejna M, Schmidinger M, Raderer M ANN ONCOL 2002 13 5 653-668
28. 786168 Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C NAT REV DRUG DISCOV 2003 2 12 999-1017
29. 786324 Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: Physiology and clinical relevance in gastrointestinal and pancreatic disorders. Low MJ BEST PRACT RES CLIN ENDOCRINOL METAB 2004 18 4 607-622
30. 786325 Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. Ben-Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S J BIOL CHEM 2005 280 25 24011-24021
31. 786328 Medical progress: Acromegaly. Melmed S N ENGL J MED 2006 355 24 2558-2573
32. 786329 Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL BR J CANCER 2005 92 8 1493-1498
33. 786330 The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW et al CLIN ENDOCRINOL 2005 63 2 176-184
34. 786729 Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Adams RL, Adams IP, Lindow SW, Atkin SL CLIN ENDOCRINOL 2004 61 4 431-436
35. 786732 Pasireotide strongly inhibits migration and proliferation of human micro- and macrovascular endothelial cells mainly via somatostatin receptor subtype 5 and FAK, ERK1/2 and p38 pathways. Pavel M, Hassler G, Schmid H, van Vugt H, Hahn E, Schuppan D ANN ENDOCR SOC MEET 2006 88 Abs P2-352
36. 786906 Merrill Lynch global pharmaceutical, biotechnology and medical device conference: Novartis oncology innovation driving growth. COMPANY PRESENTATION 2007 February 06
37. 787060 The safety, tolerability and pharmacokinetics of multiple daily doses of SOM230, a novel multi-ligand somatostatin analog. Dutreix C, Degen L, Schroller S, Wang Y, Tran LL, Beglinger C INT CONG ENDOCRINOL 2004 12 Abs P240
38. 787087 SOM230, a novel multi-ligand somatostatin analog, is well tolerated when given by continuous subcutaneous infusion. Petersenn S, Rothermel J, Unger N, Glusman J, Poon KW, Hosius C, Mann K, Tran LL INT CONG ENDOCRINOL 2004 12 Abs P239.
39. 787190 Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing's disease: Preliminary safety and efficacy results of phase II study. Boscaro M, Petersenn S, Atkinson AB, Bertherat J, Findling J, Snyder P, McBride K, Reincke M, Ludlam W, Gao B, Melmed S et al ANN ENDOCR SOC MEET 2006 88 Abs OR9-1
40. 787207 Repeated once- and twice-daily doses of the novel multi-ligand somatostatin analog SOM230 are well tolerated. Tran LL, Rothermel J, Reha A INT CONG ENDOCRINOL 2004 12 Abs P244
41. 788986 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A et al ENDOCRINE-RELATED CANCER 2007 14 1 91-102
42. 796221 The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. Kvols L, Glusman JE, Hahn EA, Oberg K, Anthony L, O'Dorisio TM, De Herder W, Darby CH, McBride K, Wiedenmann B AM SOC CLIN ONCOL 2007 43 Abs 4558
43. 802827 SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Fedele M, De Martino I, Pivonello R, Ciarmiello A, Del Basso De Caro ML, Visone R, Palmieri D, Pierantoni GM, Arra C, Schmid HA, et al CLIN CANCER RES 2007 13 9 2738-2744
44. 831963 Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Nolan LA, Schmid HA, Levy A ENDOCRINOLOGY 2007 148 6 2821-2827
45. 832316 Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727 Ono K, Suzuki T, Miki Y, Taniyama Y, Nakamura Y, Noda Y, Watanabe M, Sasano H ANTICANCER RES 2007 27 4B 2231-2239
46. 833149 Incidence and late prognosis of Cushing's syndrome: A population-based study. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P et al J CLIN ENDOCRINOL METAB 2001 86 1 117-123
47. 833160 Medical therapy of Cushing's disease. Nieman LK PITUITARY 2002 5 2 77-82
48. 833168 Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B ANN ONCOL 2004 15 6 966-973
49. 833178 Ghrelin - a hormone with multiple functions. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB FRONT NEUROENDOCRINOL 2004 25 1 27-68
50. 833196 Physiology of somatostatin receptors. Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C J ENDOCRINOL INVEST 2005 28 11 Suppl 5-9
51. 833587 Carcinoid tumors, carcinoid syndrome, and related disorders in Section 10: Paraendocrine and neoplastic syndromes. Oberg KE WILLIAMS TEXTBOOK OF ENDOCRINOLOGY - 10TH ED (EDS: LARSEN PR, KRONENBERG H, MELMED S AND POLONSKY K) 2003 Chapter 41
52. 833589 Gastrointestinal hormones and gut endocrine tumors (Chapter 38), in Section 10: Paraendocrine and neoplastic syndromes. Boushey RP, Drucker DJ WILLIAMS TEXTBOOK OF ENDOCRINOLOGY - 10TH ED (EDS: LARSEN PR, KRONENBERG H, MELMED S AND POLONSKY K) 2003 Chapter 38